معرفی
Prof. Dr. Martin Schuler serves as the Director of the Department of Medical Oncology at University Hospital Essen. He is a leading figure in oncology research, focusing on lung cancer, immuno-oncology, and biomarker-stratified clinical drug development. His work spans mechanisms of drug resistance, tumor progression, and precision medicine.
His recent publications address FGFR inhibition, KRAS G12C mutation therapies, and ctDNA applications in cancer treatment. Schuler is affiliated with the University of Duisburg-Essen, contributing to initiatives like the ACTIVE SITES research building and the Cancer Research Center Cologne Essen (CCCE).
Research Trends: His recent studies emphasize targeted therapies for solid tumors, including KRAS and EGFR mutations, FGFR alterations, and immunotherapy combinations. Key methodologies involve biomarker stratification, mRNA-based patient selection, and machine learning in immune checkpoint inhibitor response prediction.
